Literature DB >> 17138157

In vivo tetracycline labeling of bone: an intraoperative aid in the surgical therapy of osteoradionecrosis of the mandible.

Christoph Pautke1, Thomas Tischer, Andreas Neff, Hans-Henning Horch, Andreas Kolk.   

Abstract

In this technical approach, we demonstrate that preoperative tetracycline administration helps distinguish between viable and necrotic bone in osteoradionecrosis (ORN) during surgery by exciting tetracycline fluorescence by black light. The difficult aspect of the operative approach lies in the decision of the extent of the debridement in order to prevent an iatrogenic fracture or progression of ORN. With this technique, vital bone, in contrast to necrotic bone, showed detectable fluorescence. Therefore, tetracycline fluorescence labeling may be used in attempts to facilitate the intraoperative decision making in the surgical therapy of osteoradionecrosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17138157     DOI: 10.1016/j.tripleo.2006.05.007

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  3 in total

1.  Fluorescent tetracycline bone labeling as an intraoperative tool to debride necrotic bone during septic hip revision: a preliminary case series.

Authors:  Ernesto Muñoz-Mahamud; Jenaro Ángel Fernández-Valencia; Andreu Combalia; Laura Morata; Álex Soriano
Journal:  J Bone Jt Infect       Date:  2021-01-27

2.  Differences between auto-fluorescence and tetracycline-fluorescence in medication-related osteonecrosis of the jaw-a preclinical proof of concept study in the mini-pig.

Authors:  Oliver Ristow; Dirk Nehrbass; Stephan Zeiter; Daniel Arens; Julius Moratin; Christoph Pautke; Jürgen Hoffmann; Christian Freudlsperger; Sven Otto
Journal:  Clin Oral Investig       Date:  2020-05-22       Impact factor: 3.573

Review 3.  The Therapeutic Effectiveness Using Fluorescence-Guided Surgery for MRONJ.

Authors:  Hongyuan Huang; Ning Zhao; Qingxiang Li; Qiao Qiao; Jianya Zhang; Chuanbin Guo; Yuxing Guo
Journal:  Biomed Res Int       Date:  2022-09-17       Impact factor: 3.246

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.